GeoVax Reports 2025 Year-End Financial Results and Provides Business Update

Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) Scheduled to Initiate During the Second Half of This Year

Apr. 15, 2026 at 8:04pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished metal syringe, a glass vial, and a medical-grade rubber stopper, conceptually representing the development of a new vaccine.GeoVax's vaccine candidate GEO-MVA represents a critical opportunity to address the global supply shortage of orthopoxvirus vaccines.Atlanta Today

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today announced its financial results and key operational accomplishments for the year ended December 31, 2025. The company's priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, which is advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.

Why it matters

GeoVax believes GEO-MVA is uniquely positioned to address the recurring global mpox outbreaks and evolving viral strains, depleted government stockpiles following recent outbreaks, and the policy-driven demand for diversified and domestic vaccine supply. The company is actively aligning GEO-MVA with public health preparedness and biosecurity procurement frameworks, including engagement with international regulatory and governmental stakeholders.

The details

During 2025, GeoVax achieved several key milestones in advancing GEO-MVA toward late-stage development and commercial readiness, including receiving formal Scientific Advice from the European Medicines Agency (EMA) to support a streamlined and accelerated development pathway, preparing to initiate a pivotal Phase 3 clinical trial in the second half of 2026, and completing cGMP manufacturing and fill-finish of clinical-grade GEO-MVA.

  • GeoVax is preparing to initiate a pivotal Phase 3 clinical trial for GEO-MVA in the second half of 2026.
  • In April 2025, GeoVax received notification that BARDA determined to terminate the BARDA/RRPV contract for convenience to the government.

The players

GeoVax Labs, Inc.

A clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers.

David Dodd

Chairman and Chief Executive Officer of GeoVax.

Got photos? Submit your photos here. ›

What they’re saying

“During 2025, we made significant progress advancing GEO-MVA toward late-stage clinical development, supported by regulatory alignment with the European Medicines Agency (EMA) and key manufacturing milestones.”

— David Dodd, Chairman and Chief Executive Officer of GeoVax

“We believe GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines, while supporting broader public health preparedness and biosecurity objectives.”

— David Dodd, Chairman and Chief Executive Officer of GeoVax

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.